Novartis AG
Forward trial catalysts linked to NVS
CSA tracks 10 forward catalysts for Novartis AG across 6 assets, spanning Phase 3. The nearest is a readout expected Oct 26, 2026 (day precision). Confidence across its tracked catalysts breaks down as 10 medium. Tracked indications include Systemic Lupus Erythematosus, Lupus Nephritis, Atherosclerotic Cardiovascular Disease, and 12 more.
NVS in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Novartis AG has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
19 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| inclisiran | NCT04765657 | Phase 3 | Active, not recruiting | 2022-06-09 | Experimental | Novartis Pharmaceuticals | Hypercholesterolemia |
| inclisiran | NCT03705234 | Phase 3 | Active, not recruiting | 2026-10 | Experimental | University of Oxford | Atherosclerotic Cardiovascular Disease |
| inclisiran | NCT05360446 catalyst | Phase 3 | Active, not recruiting | 2026-10-26 | Experimental | Novartis Pharmaceuticals | Coronary Artery Disease |
| inclisiran | NCT07102628 catalyst | Phase 3 | Recruiting | 2027-02-11 | Experimental | Novartis Pharmaceuticals | Acute Coronary Syndrome |
| ianalumab | NCT05639114 catalyst | Phase 3 | Active, not recruiting | 2027-03-26 | Experimental | Novartis Pharmaceuticals | Systemic Lupus Erythematosus |
| tisagenlecleucel | NCT04094311 catalyst | Phase 3 | Recruiting | 2027-03-31 | Experimental | Novartis Pharmaceuticals | B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma |
| ianalumab | NCT05624749 catalyst | Phase 3 | Active, not recruiting | 2027-04-12 | Experimental | Novartis Pharmaceuticals | Systemic Lupus Erythematosus |
| iptacopan | NCT06517758 catalyst | Phase 3 | Active, not recruiting | 2027-04-30 | Experimental | Novartis Pharmaceuticals | Generalized Myasthenia Gravis |
| inclisiran | NCT05030428 catalyst | Phase 3 | Active, not recruiting | 2027-05-10 | Experimental | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease |
| pelabresib | NCT06401356 catalyst | Phase 3 | Recruiting | 2027-06-02 | Experimental | Novartis Pharmaceuticals | Hematologic Malignancy; Solid Tumor; Advanced Malignancies |
| inclisiran | NCT06813911 | Phase 3 | Recruiting | 2028-02-03 | Active comparator | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease (ASCVD) |
| remibrutinib | NCT06744920 catalyst | Phase 3 | Active, not recruiting | 2028-02-25 | Experimental | Novartis Pharmaceuticals | Generalized Myasthenia Gravis |
| inclisiran | NCT06597006 catalyst | Phase 3 | Recruiting | 2028-03-21 | Experimental | Novartis Pharmaceuticals | Familial Hypercholesterolemia - Homozygous |
| inclisiran | NCT06597019 | Phase 3 | Recruiting | 2028-03-21 | Experimental | Novartis Pharmaceuticals | Familial Hypercholesterolemia - Heterozygous |
| tisagenlecleucel | NCT05888493 | Phase 3 | Active, not recruiting | 2028-07-25 | Experimental | Novartis Pharmaceuticals | Follicular Lymphoma (FL) |
| remibrutinib | NCT07665437 | Phase 3 | Recruiting | 2031-10-24 | Experimental | Novartis Pharmaceuticals | Hidradenitis Suppurativa |
| inclisiran | NCT05682378 | Phase 3 | Recruiting | 2032-03-25 | Experimental | Novartis Pharmaceuticals | Heterozygous or Homozygous Familial Hypercholesterolemia |
| ianalumab | NCT06133972 | Phase 3 | Recruiting | 2034-04-03 | Experimental | Novartis Pharmaceuticals | Systemic Lupus Erythematosus |
| ianalumab | NCT06711887 | Phase 3 | Recruiting | 2035-08-01 | Experimental | Novartis Pharmaceuticals | Lupus Nephritis |
Every trial the CSA sample links to NVS's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →